Asthma treatment.
DOI:
https://doi.org/10.35954/SM1999.21.1.6Keywords:
Asthma; Bronchodilators; Pneumology; Cough.Abstract
An analysis of asthma treatment according to current pathogenic concepts is made; its objectives are established; anti-inflammatory drugs and bronchodilators are listed; then they are included in 2 groups: one for long-term treatment and the other for exacerbations. Finally, an asthma treatment plan by severity levels is presented.
Downloads
References
(1) National Institutes of Health National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. NIH Publication Nº 97- 4051ª May. 1997.
(2) DAVIES RJ, WANG J. et al. New insights into the understanding of asthma. Chest Suppl. 1997; 111: 2S-10S.
(3) BARNES PJ. Current therapies for asthma. Promise and limitations. Chest 1997; 111:17S-26S.
(4) HORWITZ RJ, BUSSE WW. Inflamation and asthma. Clin. Chest Med. 1995; 16(4):583.
(5) FAHY JV, BOUSHEY HA. Controversies involving inhaled B-agonists and inhaled corticosteroids in the treatment of asthma. Clin.Chest Med. 1995;16(4):715.
(6) KAMADA AK, SZFLER SJ, et al. Issues in the use of inhaled glucocorticoides. Am. J. Respir. Crit. Care Med. 1996; 153:1739-1748.
(7) DAHLEN SE. Leukotrienes as common mediators of airway obstruction evoked by many trigger factors in asthma. Rev. Eur. Respir. 1998; 8(60):369.
Published
How to Cite
Issue
Section
License
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
